Cellanome

By quantifying a cell’s genome, proteome, tran­scrip­tome, and other ​“omes” all at once — that is, by doing multiomics — inves­ti­ga­tors can find new disease biomarkers and new drug targets. Cellanome is combining its team’s expertise in sequencing, microflu­idics, sensors, synthetic biology, and informatics to build a multiomics platform that measures biological events at unprece­dented resolution and scale.